Paper Details

  1. Home
  2. Paper Details

[The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].

Author: YasudaHisataka

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review describes the mechanism of anti-RANKL antibody, specifically denosumab, in the treatment of metabolic bone diseases, including osteoporosis. Anti-RANKL antibody is highly effective in inhibiting osteoclast differentiation and is a blockbuster drug for osteoporosis and cancer-induced bone diseases. Potential applications of anti-RANKL antibody in treating cancer patients are also discussed.
Paper Details　
Original Abstract of the Article :
Discovery of RANKL (receptor activator of NF-κB ligand) gave a great impact on identification of the mechanisms regulating osteoclast differentiation and function, establishment of research field bridging bone and mineral research and immunology (osteoimmunology), and development of a fully human an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1254/fpj.153.11

データ提供：米国国立医学図書館（NLM）

RANKL: Unraveling the Mysteries of Bone Health

Hey there, fellow explorers! Dr. Camel here, ready to guide you through the fascinating world of bone health. This study focuses on the role of RANKL (receptor activator of NF-κB ligand), a protein crucial for bone remodeling. Think of RANKL as a master sculptor, constantly shaping the bone's landscape.

This research delves into the effects of denosumab, an antibody that targets RANKL. Imagine a desert caravan facing a sandstorm. Denosumab acts like a shield, protecting the caravan from the wind's relentless assault.

A Shield Against Bone Loss

The researchers found that denosumab, by blocking RANKL, is highly effective in treating osteoporosis and cancer-induced bone diseases. It's like building a protective wall against the erosion of the desert.

Strengthening the Desert's Bones

This research offers a valuable tool for maintaining bone health and preventing bone loss. It's like replenishing the desert's water reserves to ensure the growth and vitality of its ecosystem.

Dr.Camel's Conclusion

Denosumab, by targeting RANKL, provides a novel approach to combating bone loss. It's like building a sturdy oasis, a safe haven where bones can thrive and regenerate.

Date :
  1. Date Completed 2019-08-12
  2. Date Revised 2019-08-12
Further Info :

Pubmed ID

30643086

DOI: Digital Object Identifier

10.1254/fpj.153.11

Related Literature

Article Analysis
・Effective treatment of bone diseases
SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.